Citations (71)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Yoshihito Shima. (2019) The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis. Modern Rheumatology 29:2, pages 294-301.
Read now
Read now
Marta Pérez-De-Lis, Soledad Retamozo, Alejandra Flores-Chávez, Belchin Kostov, Roberto Perez-Alvarez, Pilar Brito-Zerón & Manuel Ramos-Casals. (2017) Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opinion on Drug Safety 16:11, pages 1255-1271.
Read now
Read now
Cristen B. Chafin, Nicole L. Regna, Rujuan Dai, David L. Caudell & Christopher M. Reilly. (2013) MicroRNA-let-7a expression is increased in the mesangial cells of NZB/W mice and increases IL-6 production in vitro. Autoimmunity 46:6, pages 351-362.
Read now
Read now
Noemi Busquets-Perez, Helena Marzo-Ortega & Paul Emery. (2013) Emerging drugs for axial spondyloarthritis including ankylosing spondylitis. Expert Opinion on Emerging Drugs 18:1, pages 71-86.
Read now
Read now
Joost Frans Swart, Daantje Barug, Michelle Möhlmann & Nico M Wulffraat. (2010) The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Expert Opinion on Biological Therapy 10:12, pages 1743-1752.
Read now
Read now
Yoshiyuki Ohsugi & Tadamitsu Kishimoto. (2008) The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy 8:5, pages 669-681.
Read now
Read now
Toru Mima & Norihiro Nishimoto. (2008) Tocilizumab for the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology 4:2, pages 165-172.
Read now
Read now
Stefan Rose-John, Georg H Waetzig, Jürgen Scheller, Joachim Grötzinger & Dirk Seegert. (2007) The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opinion on Therapeutic Targets 11:5, pages 613-624.
Read now
Read now
Articles from other publishers (63)
Rainer H. StraubRainer H. Straub. 2023. Early Trauma as the Origin of Chronic Inflammation. Early Trauma as the Origin of Chronic Inflammation
135
231
.
Rainer H. StraubRainer H. Straub. 2022. Frühe Traumata als Ursprung von chronischer Entzündung. Frühe Traumata als Ursprung von chronischer Entzündung
141
243
.
Naim Mahroum, Abdulla Watad, Charlie Bridgewood, Muhammad Mansour, Ahmad Nasr, Amr Hussein, Rola Khamisy-Farah, Raymond Farah, Omer Gendelman, Merav Lidar, Yehuda Shoenfeld, Howard Amital, Jude Dzevela Kong, Jianhong Wu, Nicola Luigi Bragazzi & Dennis McGonagle. (2021) Systematic Review and Meta-Analysis of Tocilizumab Therapy versus Standard of Care in over 15,000 COVID-19 Pneumonia Patients during the First Eight Months of the Pandemic. International Journal of Environmental Research and Public Health 18:17, pages 9149.
Crossref
Crossref
Yinshi Ren, Zhuo Deng, Vishal Gokani, Michael Kutschke, Thomas Wesley Mitchell, Olumide Aruwajoye, Naga Suresh Adapala, Nobuhiro Kamiya, Yousef Abu‐Amer & Harry KW Kim. (2020)
Anti‐Interleukin‐
6
Therapy Decreases Hip Synovitis and Bone Resorption and Increases Bone Formation Following Ischemic Osteonecrosis of the Femoral Head
. Journal of Bone and Mineral Research 36:2, pages 357-368.
Crossref
Crossref
Samvedna Saini & Yatender Kumar. 2021. Translational Biotechnology. Translational Biotechnology
233
266
.
Michael Levy. (2020) Interleukin-6 receptor blockade for the treatment of NMOSD. The Lancet Neurology 19:5, pages 370-371.
Crossref
Crossref
Juliane Gust, Francesco Ceppi & Cameron J. Turtle. 2020. Chimeric Antigen Receptor T-Cell Therapies for Cancer. Chimeric Antigen Receptor T-Cell Therapies for Cancer
83
105
.
Haruna SHIRAKO, Yuko UDAKA, Akiko SASAKI, Shota NAKAMURA, Mayumi TSUJI & Yuji KIUCHI. (2019) Comparison of Anti-Inflammatory Analgesics for Mechanical Stress-induced Inflammation in a Human Synovial Sarcoma Cell Line. The Showa University Journal of Medical Sciences 31:1, pages 51-62.
Crossref
Crossref
Juliane Gust, Agne Taraseviciute & Cameron J. Turtle. (2018) Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies. CNS Drugs 32:12, pages 1091-1101.
Crossref
Crossref
Yoshito KOBAYASHI, Yuko UDAKA, Haruna SHIRAKO, Miki KATO, Yoshiko KUDO, Nana ICHIMURA, Mayumi TSUJI & Yuji KIUCHI. (2018) Establishment of a Mechanical Stress Load Arthritis Model in a Human Synovial Sarcoma Cell Line. The Showa University Journal of Medical Sciences 30:1, pages 63-72.
Crossref
Crossref
Srinath Kasturirangan, G. Jonah Rainey, Linda Xu, Xinwei Wang, Alyse Portnoff, Tracy Chen, Christine Fazenbaker, Helen Zhong, Jared Bee, Zhutian Zeng, Craig Jenne, Herren Wu & Changshou Gao. (2017) Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody. Journal of Biological Chemistry 292:10, pages 4361-4370.
Crossref
Crossref
Li-Teng Ong, Hui-Foon Tan, Chen Feng, Jing Qu, Shuzk-Cheng Loh, Surajit Bhattacharyya & Suet-Mien Tan. (2017) The Systemic Lupus Erythematosus–Associated Single Nucleotide Polymorphism rs1143678 in Integrin αM Cytoplasmic Tail Generates a 14-3-3ζ Binding Site That Is Proinflammatory. The Journal of Immunology 198:2, pages 883-894.
Crossref
Crossref
S. Könemann, M. Dörr & S.B. Felix. 2017. The Heart in Rheumatic, Autoimmune and Inflammatory Diseases. The Heart in Rheumatic, Autoimmune and Inflammatory Diseases
681
714
.
Nozomu Yanaihara, Yukihiro Hirata, Noriko Yamaguchi, Yukiko Noguchi, Misato Saito, Chie Nagata, Satoshi Takakura, Kyosuke Yamada & Aikou Okamoto. (2016) Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary. Molecular Carcinogenesis 55:5, pages 832-841.
Crossref
Crossref
MA El-Ganzuri, RR Ahmed & EM Bastawy. (2016) Regulatory Mechanisms of Bone Development and Function. Annals of Cytology and Pathology 1:1, pages 005-017.
Crossref
Crossref
Toral P. Kobawala, Trupti I. Trivedi, Kinjal K. Gajjar, Darshita H. Patel, Girish H. Patel & Nandita R. Ghosh. (2016) Significance of Interleukin-6 in Papillary Thyroid Carcinoma. Journal of Thyroid Research 2016, pages 1-12.
Crossref
Crossref
K. Tenbrock. (2015) Klinik und Therapie rheumatischer Erkrankungen und Vaskulitiden im KindesalterClinical features and therapy of rheumatic diseases and vasculitides in childhood. rheuma plus 14:2, pages 32-39.
Crossref
Crossref
Michael R Takeno & Jacob B Gunn. (2015) A novel role of peptidyl-prolyl isomerase-1 as inducer of IL-6 expression in systemic lupus erythematosus. American Journal of BioMedicine 3:2, pages 439-450.
Crossref
Crossref
Tyesha N. Burks, Ruth Marx, Laura Powell, Jasma Rucker, Djahida Bedja, Elisa Heacock, Barbara J. Smith, D. Brian Foster, David Kass, Brian O’Rourke, Jeremy D. Walston & Peter M. Abadir. (2015) Combined effects of aging and inflammation on renin-angiotensin system mediate mitochondrial dysfunction and phenotypic changes in cardiomyopathies. Oncotarget 6:14, pages 11979-11993.
Crossref
Crossref
Ni Zhang, Ning Yang, Qilin Chen, Feng Qiu & Xingfu Li. (2014) Upregulated expression level of the growth factor, progranulin, is associated with the development of primary Sj�gren's syndrome. Experimental and Therapeutic Medicine.
Crossref
Crossref
K. Tenbrock. (2014) Klinik und Therapie rheumatischer Erkrankungen und Vaskulitiden im KindesalterClinical features and therapy of rheumatic diseases and vasculitides in childhood. Der Hautarzt 65:9, pages 802-809.
Crossref
Crossref
Erik Tandberg Askevold, Lars Gullestad, Christen P. Dahl, Arne Yndestad, Thor Ueland & P?l Aukrust. (2014) Interleukin-6 Signaling, Soluble Glycoprotein 130, and Inflammation in Heart Failure. Current Heart Failure Reports 11:2, pages 146-155.
Crossref
Crossref
Waseem Hassan, Lin Ding, Rong-Yin Gao, Jun Liu & Jing Shang. (2014) Interleukin-6 signal transduction and its role in hepatic lipid metabolic disorders. Cytokine 66:2, pages 133-142.
Crossref
Crossref
Chieh-Shan Wu, Yi-Rong Li, Jeremy J.W. Chen, Ying-Che Chen, Chiang-Liang Chu, I-Hong Pan, Yu-Shan Wu & Chi-Chen Lin. (2014) Antihelminthic niclosamide modulates dendritic cells activation and function. Cellular Immunology 288:1-2, pages 15-23.
Crossref
Crossref
Feng Qiu, Lijun Song, Feng Ding, Huaxiang Liu, Qiang Shu, Ning Yang, Weiwei Liu & Xingfu Li. (2013) Expression level of the growth factor progranulin is related with development of systemic lupus erythematosus. Diagnostic Pathology 8:1.
Crossref
Crossref
Jaime Calvo-Alén, Lucía Silva-Fernández, Eduardo Úcar-Angulo, José María Pego-Reigosa, Alejandro Olivé, Carmen Martínez-Fernández, Víctor Martínez-Taboada, José Luis Marenco, Estíbaliz Loza, Javier López-Longo, Juan Jesús Gómez-Reino, María Galindo-Izquierdo, Antonio Fernández-Nebro, María José Cuadrado, María Ángeles Aguirre-Zamorano, Antonio Zea-Mendoza & Íñigo Rúa-Figueroa. (2013) SER Consensus Statement on the Use of Biologic Therapy for Systemic Lupus Erythematosus. Reumatología Clínica (English Edition) 9:5, pages 281-296.
Crossref
Crossref
Jaime Calvo-Alén, Lucía Silva-Fernández, Eduardo Úcar-Angulo, José María Pego-Reigosa, Alejandro Olivé, Carmen Martínez-Fernández, Víctor Martínez-Taboada, José Luis Marenco, Estíbaliz Loza, Javier López-Longo, Juan Jesús Gómez-Reino, María Galindo-Izquierdo, Antonio Fernández-Nebro, María José Cuadrado, María Ángeles Aguirre-Zamorano, Antonio Zea-Mendoza & Íñigo Rúa-Figueroa. (2013) Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico. Reumatología Clínica 9:5, pages 281-296.
Crossref
Crossref
Peter L. Thompson, S. Mark Nidorf & John Eikelboom. (2013) Targeting the Unstable Plaque in Acute Coronary Syndromes. Clinical Therapeutics 35:8, pages 1099-1107.
Crossref
Crossref
Mitsuaki Yanagida, Mikiko Kawasaki, Maki Fujishiro, Masako Miura, Keigo Ikeda, Kazuhisa Nozawa, Hiroshi Kaneko, Shinji Morimoto, Yoshinari Takasaki, Hideoki Ogawa, Kenji Takamori & Iwao Sekigawa. (2013) Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody. BioMed Research International 2013, pages 1-9.
Crossref
Crossref
Mami Noda, Yukiko Yamakawa, Naoya Matsunaga, Satoko Naoe, Taishi Jodoi, Megumi Yamafuji, Nozomi Akimoto, Norihiro Teramoto, Kyota Fujita, Shigehiro Ohdo & Haruo Iguchi. (2012) IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. International Journal of Molecular Sciences 14:1, pages 515-526.
Crossref
Crossref
Yuqi Guo, Feng Xu, TianJian Lu, Zhenfeng Duan & Zhan Zhang. (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treatment Reviews 38:7, pages 904-910.
Crossref
Crossref
Mitsuaki Yanagida, Giman Jung, Yoshinori Tanaka, Saburo Sone, Maki Fujishiro, Keigo Ikeda, Kazuhisa Nozawa, Hiroshi Kaneko, Yoshinari Takasaki, Hideoki Ogawa, Kenji Takamori & Iwao Sekigawa. (2012) Serum proteome analysis in patients with rheumatoid arthritis receiving therapy with etanercept, a chimeric tumor necrosis factor‐alpha receptor. International Journal of Rheumatic Diseases 15:5, pages 486-495.
Crossref
Crossref
Masahiko Mihara, Misato Hashizume, Hiroto Yoshida, Miho Suzuki & Masashi Shiina. (2011) IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clinical Science 122:4, pages 143-159.
Crossref
Crossref
Fernando Lekpa, C?cile Poulain, Daniel Wendling, Martin Soubrier, Michel De Bandt, Jean Berthelot, Philippe Gaudin, Eric Toussirot, Philippe Goupille, Thao Pham, J?r?mie Sellam, R?my Bruckert, Muriel Paul, Val?rie Farrenq & Pascal Claudepierre. (2012) Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? a multicentre retrospective observational study. Arthritis Research & Therapy 14:2, pages R53.
Crossref
Crossref
Valérie Schaeffer, Saman Arbabi, Iris A. Garcia, Megan L. Knoll, Joseph Cuschieri, Eileen M. Bulger & Ronald V. Maier. (2011) Role of the mTOR Pathway in LPS-Activated Monocytes: Influence of Hypertonic Saline. Journal of Surgical Research 171:2, pages 769-776.
Crossref
Crossref
Hirotake Takai, Atsuhiko Kato, Teruo Nakamura, Tatsuhiko Tachibana, Takayuki Sakurai, Masahiko Nanami & Masami Suzuki. (2011) The importance of characterization of FITC-labeled antibodies used in tissue cross-reactivity studies. Acta Histochemica 113:4, pages 472-476.
Crossref
Crossref
Kim Ohl & Klaus Tenbrock. (2011) Inflammatory Cytokines in Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology 2011, pages 1-14.
Crossref
Crossref
E. Brietzke, M. Scheinberg & B. Lafer. (2011) Therapeutic potential of interleukin-6 antagonism in bipolar disorder. Medical Hypotheses 76:1, pages 21-23.
Crossref
Crossref
Peter L. Thompson. 2011. Acute Coronary Syndromes: A Companion to Braunwald's Heart Disease. Acute Coronary Syndromes: A Companion to Braunwald's Heart Disease
289
298
.
Angus G. Thompson & Peter L. Thompson. 2011. Coronary Care Manual. Coronary Care Manual
338
345
.
Markus B?hm & Thomas A. Luger. 2011. Rheumatology. Rheumatology
285
295
.
Dipak R Patel & Bruce C Richardson. (2010) Epigenetic mechanisms in lupus. Current Opinion in Rheumatology 22:5, pages 478-482.
Crossref
Crossref
Aurelia Lartigue, Natacha Colliou, Sébastien Calbo, Arnault François, Serge Jacquot, Christophe Arnoult, Francois Tron, Daniele Gilbert & Philippe Musette. (2009)
Critical Role of TLR2 and TLR4 in Autoantibody Production and Glomerulonephritis in
lpr
Mutation-Induced Mouse Lupus
. The Journal of Immunology 183:10, pages 6207-6216.
Crossref
Crossref
Atsuhiko Kato, Takeshi Watanabe, Masaki Yamazaki, Toshiaki Deki & Masami Suzuki. (2009) IL-6R distribution in normal human and cynomolgus monkey tissues. Regulatory Toxicology and Pharmacology 53:1, pages 46-51.
Crossref
Crossref
T. Yoshimura, K.-H. Sonoda, N. Ohguro, Y. Ohsugi, T. Ishibashi, D. J. Cua, T. Kobayashi, H. Yoshida & A. Yoshimura. (2009) Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology 48:4, pages 347-354.
Crossref
Crossref
Yoshiyuki OhsugiTadamitsu Kishimoto. (2009) Pharmacotherapy Options in Rheumatoid Arthritis: Focus on Tocilizumab, a Recombinant Humanized Anti-Interleukin-6 Receptor Antibody. Clinical Medicine. Therapeutics 1, pages CMT.S2048.
Crossref
Crossref
Masahiko Mihara, Yoshiyuki Ohsugi & Tadamitsu Kishimoto. (2009) Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti‐interluekin‐6 receptor antibody. BioFactors 35:1, pages 47-51.
Crossref
Crossref
Anthony Sebba. (2008) Tocilizumab: The first interleukin-6-receptor inhibitor. American Journal of Health-System Pharmacy 65:15, pages 1413-1418.
Crossref
Crossref
Georg Pongratz & Rainer H. Straub. (2007) B-cell involvement in the pathogenesis of RA–is there a contribution of the sympathetic nervous system?. Immunologic Research 40:2, pages 148-163.
Crossref
Crossref
Meera Ramanujam & Anne Davidson. (2008) Targeting of the immune system in systemic lupus erythematosus. Expert Reviews in Molecular Medicine 10.
Crossref
Crossref
Reinhard Gruber, Peter Pietschmann & Meinrad Peterlik. 2008. Radiology of Osteoporosis. Radiology of Osteoporosis
1
23
.
Bevra Hahn & Sonwoo Lee. 2007. Contemporary Targeted Therapies in Rheumatology. Contemporary Targeted Therapies in Rheumatology
435
447
.
Geza P Balint & Peter V Balint. (2007) Tocilizumab: a new form of biological therapy for rheumatoid arthritis. Future Rheumatology 2:4, pages 361-371.
Crossref
Crossref
Tomoshige Kino, Terrence L. Boos, Agnieszka Sulima, Elise M. Siegel, Philip W. Gold, Kenner C. Rice & George P. Chrousos. (2007) 3-O-Formyl-20R,21-epoxyresibufogenin suppresses IL-6?type cytokine actions by targeting the glycoprotein 130 subunit: Potential clinical implications. Journal of Allergy and Clinical Immunology 120:2, pages 437-444.
Crossref
Crossref
Val??rie Schaeffer, Joseph Cuschieri, Iris Garcia, Megan Knoll, Jens Billgren, Sandra Jelacic, Eileen Bulger & Ronald Maier. (2007) THE PRIMING EFFECT OF C5A ON MONOCYTES IS PREDOMINANTLY MEDIATED BY THE P38 MAPK PATHWAY. Shock 27:6, pages 623-630.
Crossref
Crossref
Margaret Wisłowska & Danuta Jakubicz. (2007) Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-α blocker plus methotrexate versus methotrexate or leflunomide alone. Rheumatology International 27:7, pages 641-647.
Crossref
Crossref
Wenhui Wu, Luise Weigand, Yasmine Belkaid & Susana Mendez. (2006)
Immunomodulatory effects associated with a live vaccine against
Leishmania major
containing CpG oligodeoxynucleotides
. European Journal of Immunology 36:12, pages 3238-3247.
Crossref
Crossref
Bailin Liang, Debra B. Gardner, Don E. Griswold, Peter J. Bugelski & Xiao Yu R. Song. (2006) Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 119:3, pages 296-305.
Crossref
Crossref
Philip Mease. (2006) Management of psoriatic arthritis: The therapeutic interface between rheumatology and dermatology. Current Rheumatology Reports 8:5, pages 348-354.
Crossref
Crossref
Jeffrey L. Browning. (2006) B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature Reviews Drug Discovery 5:7, pages 564-576.
Crossref
Crossref
Marcello Maggio, Jack M. Guralnik, Dan L. Longo & Luigi Ferrucci. (2006) Interleukin-6 in Aging and Chronic Disease: A Magnificent Pathway. The Journals of Gerontology: Series A 61:6, pages 575-584.
Crossref
Crossref
Rainer H. Straub, Peter Härle, Seizo Yamana, Takemasa Matsuda, Kiyoshi Takasugi, Tadamitsu Kishimoto & Norihiro Nishimoto. (2006) Anti–interleukin‐6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: A randomized, double‐blind, placebo‐controlled study. Arthritis & Rheumatism 54:6, pages 1778-1785.
Crossref
Crossref
Yoshiyuki Ohsugi & Nobuyuki Tsuchimoto. (2005) . Folia Pharmacologica Japonica 126:6, pages 419-425.
Crossref
Crossref